Intensive Glycemic Control and Mortality in Critically Ill Patients: A Review of Pivotal Evidence

Abstract

Introduction: Hyperglycemia is a frequent complication in critically ill patients and is independently associated with adverse outcomes. This observation led to a period of intense clinical investigation to determine whether aggressive normalization of blood glucose levels using intensive insulin therapy could improve survival in the intensive care unit (ICU).

Literature Review: A review of the pivotal literature reveals a remarkable scientific arc. A landmark single-center trial initiated a paradigm shift by reporting a dramatic reduction in mortality with intensive glycemic control compared to conventional management. This finding prompted widespread, enthusiastic adoption of tight glucose control protocols in ICUs globally. However, subsequent trials in different patient populations reported more modest or no survival benefit, while consistently highlighting a significant increase in the risk of severe hypoglycemia. This clinical equipoise was ultimately addressed by a large, international, multi-center randomized trial. This definitive study demonstrated that tight glucose control did not reduce mortality; conversely, it resulted in a significant increase in mortality compared to a moderate control strategy, alongside a much higher incidence of hypoglycemia.

Conclusion: The body of evidence illustrates a complete scientific cycle of discovery, validation, and refutation. It demonstrates that the initial promise of intensive glycemic control was not substantiated in broader, more pragmatic trials and revealed an important safety risk. This research fundamentally reshaped clinical practice, establishing a safer, more moderate approach to glucose management in the critically ill.